Ascendia Pharmaceuticals is featured prominently in the 2021 edition of the United States Pharmaceutical and Biopharmaceutical Industry Report published by Global Business Report (GBR). The annual digest, which was released in May, provides widespread coverage of the state of the U.S. pharmaceutical and biopharmaceutical industry.
Ascendia Chief Business Officer Robert Bloder was included in the report’s feature article on CDMO M&A and Investment. He explained Ascendia recently received a growth PE investment from the esteemed Signet Healthcare Partners to grow and expand its staff, capabilities, and facilities. The support of Signet Healthcare Partners will help Ascendia continue to meet and exceed customer expectations from early to late stage development.
The digest also conducted a Q&A with Bloder to discuss the success Ascendia has experienced in the past three years, as well as the company’s growth plans moving forward. He explained Ascendia’s technical prowess that includes proprietary nanotechnologies, service-oriented culture, and flexibility, and how that approach has 
begun to make the impossible possible for many clients. Ascendia has built its sound reputation one project at a time, with Ascendia being anointed a “Partner of Choice,” as noted in the interview.
Contact us to learn more on our culture and technologies and how Ascendia can help with your next project.